Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

As an unplanned overall survival (OS) analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with ...